SLNO rated highest in P/B Growth Investor model based on Partha Mohanram's strategy.

From Nasdaq: 2025-04-05 15:05:00

Validea’s guru fundamental report for SOLENO THERAPEUTICS INC (SLNO) shows it rates highest in the P/B Growth Investor model based on Partha Mohanram’s strategy, with a 55% rating. SLNO is a mid-cap growth stock in Biotechnology & Drugs. The stock meets some criteria like cash flow from operations to assets, return on assets variance, and research and development to assets, but falls short on others like sales variance and advertising to assets. Partha Mohanram, known for his research in growth investing, has a model that has produced significant market outperformance. Validea is an investment research service that follows strategies of investment legends.



Read more at Nasdaq: SLNO Quantitative Stock Analysis | Nasdaq